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ABSTRACT (Word count = 248) 
Objective: Many studies that have estimated the breast cancer risk attributable to family history 
have been based on data collected within family units. Use of this study design has likely 
overestimated risks for the general population. We provide population-based estimates of breast 
cancer risk and different tumor subtypes in relation to the degree, number, and age at diagnosis 
of affected relatives.  
Methods:  Cox Proportional Hazards to calculate risks (hazard ratios; 95% confidence interval) 
of breast cancer and tumor subtypes for women with a family history of breast cancer relative to 
women without a family history among a cohort of 75,189 women age ≥40 years of whom 1,087 
were diagnosed with breast cancer from June 1, 2001-December 31, 2005 (median follow-up 
3.16 years). 
Results: Breast cancer risk was highest for women with a first-degree family history (1.54; 1.34-
1.77); and did not differ substantially by the affected relative’s age at diagnosis or by number of 
affected first-degree relatives.  A second-degree family history only was not associated with a 
significantly increased breast cancer risk (1.15; 0.98-1.35). There was a suggestion that a 
positive family history was associated with risk of triple positive (Estrogen+/Progesterone+/ 
HER2+) and HER2-overexpressing tumors. 
Conclusions:  While a family history of breast cancer in first-degree relatives is an important 
risk factor for breast cancer, gathering information such as the age at diagnosis of affected 
relatives or information on second-degree relative history may be unnecessary in assessing 
personal breast cancer risk among women age ≥40 years.  
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INTRODUCTION 
A family history of breast cancer has long been considered an important risk factor for 
breast cancer.  Research indicates that women with an affected first-degree relative 
(mother/father/sister/brother/daughter/son) or with any affected family member diagnosed <50 
years have particularly high risks [1-7]. These associations may reflect a combination of factors, 
including high-penetrance inherited genetic mutations in genes such as BRCA1 and BRCA2, 
low-penetrance inherited mutations in genes such as GSTP1, and a shared family environment 
[8].  
Estimates of the amount of increased breast cancer risk attributable to family history 
have varied by study design, population, and sample size [6].  Analyses of family-based studies, 
which systematically identify cases (probands) within families, may lead to inflated risk 
estimates since families under study may have unmeasured risk factors and/or high-risk genetic 
mutations [9]. Risk estimates obtained from population-based studies should be more robust 
and generalizable than risk estimates from family-based studies.  
Population-based data from around the world has been comprehensively evaluated in a 
meta-analysis using data from 52 case-control and 22 cohort studies.  Based on this analysis, 
women with a first-degree family history of breast cancer had a 2.1-fold (95% confidence 
interval (CI): 2.0–2.2) increased risk of breast cancer and women with a second-degree family 
history had a 1.5-fold (95%CI: 1.4–1.6) increased risk compared to women with no family history 
of breast cancer [6]. This meta-analysis was unable to explore the risks associated with having 
both a first and second-degree family history or having different numbers of affected family 
members of varying degrees.  This meta-analysis also did not adjust for a woman’s total number 
of relatives (affected and unaffected) or mammographic breast density.  
Family history of breast cancer may be predictive of additional risk factors for breast 
cancer, such as breast density [10], and may predispose women to particular types of breast 
cancer, specifically breast tumors not over-expressing (-) estrogen and progesterone hormone 
  
5 
receptors (ER/PR) or over-expressing (+) the proto-oncogene HER2-neu (HER2) [11-15].  
Studies examining the relation between family history and ER/PR status have generally found 
no association, but have been limited by their sample sizes [16], and only one has evaluated the 
relation between family history and ER, PR, and HER2 status [15]. Identifying risk factors for 
molecular subtypes of breast cancer with particularity poor prognoses, HER2 over-expressing 
(ER−/PR−/HER2+) and basal type (ER−/PR−/HER2−) breast cancers [17-18], is important since 
risk factor data are currently lacking.   
We studied the association between a woman’s family history of breast cancer and her 
breast cancer risk in a population-based setting.  We were able to take into account precise 
kinship of affected relatives (i.e., mother, sister, grandmother, aunt), degree of relationship of 
affected relatives (i.e., first or second), total number of relatives by degree, and whether 
relatives were diagnosed with breast cancer before age 50.   
  
6 
METHODS 
Study Subjects and Setting 
This study was conducted among members of Group Health, a large integrated health 
plan in Western Washington State. Since 1986, women aged ≥40 years have been invited to 
enroll in a breast cancer screening program, which involves automated recruitment and 
reminder letters for women to initiate screening mammography [19-20].  As part of the 
screening program, women fill out a breast cancer risk factor questionnaire including detailed 
family history information.  The questionnaire does not assess the maternal or paternal lineage 
of potentially affected aunts and grandmothers. 
The questionnaire has two modes of administration: mailed and in-clinic. Women 
receive mailed questionnaires when they turn 40 years of age or upon enrollment in the health 
plan (if ≥40 years).  Women also fill out risk factor questionnaires at each mammogram.  Based 
on the information provided on these questionnaires, each woman receives reminders to get 
screening mammograms on risk-based screening intervals [19-20]. During this study, all 
women ≥50 years, and women between 40 and 49 years who were nulliparous, had an 
affected first or second-degree relative, menarche <11 years, were aged >30 years at first 
birth, or had a previous negative breast biopsy, received reminders for screening every two 
years.  All other women <50 years were not recommended for routine screening 
mammography, but could still receive annual mammography.  During this same time, all 
women ≥40 years with ≥2 affected first-degree relatives or atypical hyperplasia on a previous 
breast biopsy were reminded for screening annually [21-22].    
All women aged ≥40 years that completed a questionnaire between 6/1/2001-
12/31/2005, were eligible for inclusion in this study (N = 94,891).  We excluded women from 
the analyses for the following reasons: reported “unknown” family history of breast cancer for 
all relatives (n=10,166), family history portion of the questionnaire was not completed 
(n=2,853), prior diagnosis of breast cancer (N=4,477), adopted and did not know the family 
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history of their biological relatives (n=1,875), did not consent to have their data used for 
research (n=187), or had a previous unilateral or bilateral mastectomy (n=164).  
All women entered the study on the date of their first completed questionnaire after 
June 1, 2001 and were followed until the first of the following: 1) breast cancer diagnosis 
(event), 2) disenrollment from Group Health (censored), 3) death (censored), or 4) end of 
follow-up (censored at end of study period December 31, 2005). The Group Health Institutional 
Review Board approved all analyses and data collection for this study.  
Breast Cancer Data 
We identified all invasive and in situ breast cancer diagnoses in the cohort by linking 
records from the Western Washington Surveillance Epidemiology and End Results Reporting 
(SEER) registry. We used SEER data to characterize the tumors including ER and PR status, 
stage at diagnosis, tumor size, and lymph node involvement.  HER2 over-expression status 
was abstracted from medical records at Group Health for a subgroup of women (44.3% of total, 
N=482). 
Family History Definitions 
Women were considered to have a positive family history of breast cancer if they 
reported they had a mother, sister, aunt, or grandmother diagnosed with breast cancer.  
Affected fathers, brothers, and daughters were not included in our definition of a positive family 
history and analyses due to sample size.  These specific relatives were also excluded from 
contributing to a woman’s total number of relatives, both unaffected and affected, in all 
analyses. Family history exposures are described in detail in Appendix A.  In all analyses, 
women with no reported breast cancer family history were the referent group.  We examined 
risk associated with the following exposures: 1) First-degree family history a) alone and in 
combination with second degree family history; b) by number of relatives, and c) by age at 
diagnosis of affected relatives; 2) Second-degree family history a) alone; b) by number of 
relatives, and c) by age at diagnosis of affected relatives; and 3) Specific relative history a) by 
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number of specific relatives, and b) by age of diagnosis of specific relatives.  Analyses 
involving the number of affected sisters and aunts included only subjects with ≥1 sister or aunt.  
Statistical Analysis 
We used Cox Proportional Hazards models to estimate hazard ratios (HR) and 95% CIs 
for the association between family history and subsequent risk of a breast cancer diagnosis 
[23].  We explored potential associations between family history of breast cancer and risk of 
having an ER+/PR+, ER+/PR−, or ER−/PR− tumor among women with known ER and PR 
receptor status (N=858); we excluded women with ER−/PR+ tumors from this analysis due to 
the rarity of this subtype (N=11).  We also explored the risk of having a Luminal A (ER+ and/or 
PR+ and HER2+), Luminal B (ER+ and/or PR+ and HER2−), HER2 over-expressing (ER−, 
PR−, and HER2+), or basal-type tumor (ER−, PR−, and HER2−) among women with available 
data for ER, PR, and HER2 status (N= 482) [24-25].  
A list of potential confounders was determined a priori based on established breast 
cancer risk factors from the literature [8].  We explored potential confounding by age at 
baseline (quadratic), menopausal status (pre or peri-menopausal/post-menopausal), age at 
first birth (nulliparous/<30/≥30 years), benign breast biopsy history (yes/no), hormone therapy 
use (ever/never), age at menarche (<12/13/14/≥15), body mass index (BMI) (kg/m2, 
continuous), breast density (almost entirely fat/scattered fibroglandular/heterogeneously 
dense/extremely dense) [26], and time since last mammogram (<3/≥3 years).  For women with 
missing menopausal status information, we categorized women as post-menopausal if they 
were ≥55 years, reported prior use of hormone therapy, or reported a bilateral oophorectomy.   
We also explored adjustment for each woman’s total number of female relatives by 
using covariates that represented the total number (both unaffected and affected) of first-
degree, second-degree, and specific types of female relatives that each woman reported.  
However, adjustment for these potential confounders and family size covariates did not notably 
alter risk estimates, so we only present age-adjusted risk estimates.  
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Women whose baseline risk information was obtained from a mailed questionnaire were 
more likely to be younger than age 50 (53.8% vs. 29.1%) and pre/peri-menopausal (48.0% vs. 
29.6%) than were women whose baseline risk information was obtained from an in-clinic 
questionnaire.  As a result, these women had substantially different crude baseline hazards for 
subsequent breast cancer diagnoses (202 and 523 events per 100,000 person-years, 
respectively).  To account for these differences, all analyses were implicitly stratified by 
questionnaire source to allow the baseline hazards for these groups of women to differ [27].  We 
examined potential effect modification by questionnaire source, menopausal status, hormone 
therapy use and subject age (50/60/65/70/80 years) but found no statistically significant 
interactions. 
All final models were examined for violations of the proportional hazards assumptions.  
No statistically significant deviations from proportional hazards were observed for standardized 
and non-standardized residuals on the time, log-time or rank scale.  We examined pairwise 
comparisons to assess the difference between risk estimates across family history using Wald 
tests at a significance level of 0.05.  All analyses were conducted in Stata SE, version 9.0 [28].  
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RESULTS 
 Among 75,169 women with a total of 218,424 person-years at risk, 1,087 women were 
diagnosed with breast cancer (Table 1).  Relative to the entire cohort, women diagnosed with 
breast cancer were more likely to be older, postmenopausal, current users of estrogen and 
progestin hormone therapy, to have heterogeneously dense breasts, and to have a history of 
benign breast biopsy.  Women diagnosed with breast cancer were also more likely to have had 
a screening or negative diagnostic mammogram in the three years before study entry (69.1% 
vs. 65.9%). The distributions of race, BMI, age at menarche, and age at first birth did not differ 
by breast cancer diagnosis.  
In our cohort of 75,169 women with known family history, 19.5% (N=14,675) reported 
having a first-degree family history and 21.4% (N=16,073) reported having only a second-
degree family history (Table 2).  Having a first-degree family history, with or without a second-
degree family history, was associated with an increased breast cancer risk (HR=1.54; 95%CI: 
1.34–1.77) compared to having no family history of breast cancer after adjusting for age of study 
subject at study entry. Neither the number of affected first-degree relatives nor the relative’s 
age(s) at diagnosis substantially modified this risk (p-values 0.30 and 0.47, respectively). 
Women with second-degree family history only did not have a significantly higher risk of breast 
cancer than women with no family history (HR=1.15; 95%CI: 0.98–1.35), regardless of the 
number of affected second-degree relatives or their relative’s age(s) at diagnosis.  There was no 
significant difference in risk estimates when stratified by a woman’s age at study entry.  
 Women whose mothers were diagnosed with breast cancer had a 56% higher risk of 
breast cancer than did women with no family history (95%CI: 1.31–1.86) (Table 3), with no 
significant difference in risk by maternal age of diagnosis (p-value = 0.96).  The risk associated 
with having two affected grandmothers was significantly higher than the risk associated with 
having only one affected grandmother (p-value = 0.04).  Among women with >1 sister or aunt, 
the risk among women with 1 affected sister/aunt was not significantly different than the risk 
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among those with ≥2 affected sisters/aunts (p-values = 0.37 and 0.91, respectively) compared 
to women with no affected sisters/aunts. 
After adjusting for age, women with a first-degree family history had increased risks of 
ER+/PR+ and ER+/PR− tumors, but not ER−/PR− tumors, compared to women with no family 
history (Table 4).  Women with only a second-degree family history were not at an increased 
risk for any of the ER/PR tumor subtypes compared to women with no family history. Women 
with a first-degree family history experienced higher risks of Luminal A tumors compared to 
women with no family history (Table 5).  There was also a suggestion that first-degree family 
history was related to risks of both Luminal B and HER2 over-expressing tumors (but not to risk 
of basal-type disease), though these risk estimates were within the limits of chance and are 
based on a small number of individuals. 
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DISCUSSION 
In contrast to much of the published literature [2-3,6,29], our breast cancer risk 
estimates associated with family history of breast cancer assessed among women ≥40 years 
are uniformly lower in magnitude. Our results suggest that detailed collection of information on 
affected relative’s age(s) at diagnosis and in second-degree relatives is not needed for disease 
free women ≥40.  In our study, age at diagnosis of affected relatives did not significantly alter 
breast cancer risk and women with only a second-degree family history of breast cancer, in the 
absence of a first-degree history, were not at an increased risk for breast cancer.  Although 
previous studies [1-2,5-7,29-30] suggest breast cancer risk is greater among women with first 
or second-degree relatives that have a younger age at diagnosis (i.e., <50 vs. ≥50 years), our 
estimates of these same risks were not significantly different from one another. Therefore our 
results may have important implications for streamlining the risk assessment of women ≥40 
years during clinical care. 
Our results suggest the ability to predict individuals with a high breast cancer risk would 
not be substantially improved by the collection of breast cancer history in second-degree 
relatives or the age at diagnosis of affected relatives.  A simplified assessment of family history 
(i.e., only asking whether any mother, sister or aunt has been diagnosed with breast cancer) 
may adequately determine each woman’s breast cancer risk attributable to family history once 
women have reached age 40.  While detailed family history assessment may be crucial for 
certain diseases, our results suggest that detailed records of breast cancer history in second-
degree relatives may be unnecessary, especially since the accuracy of self-reported second 
degree history may be questionable [31-32].  
Worth noting is our finding that women who reported having two affected grandmothers 
experienced a significantly greater breast cancer risk than did women with only one affected 
grandmother, regardless of the grandmothers’ age(s) at diagnosis.  Although we did not gather 
information on lineage for the relatives in our study, the higher risk associated with having two 
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affected grandmothers suggests the presence of disease in both maternal and paternal 
relatives is associated with a substantially increased risk. The notably different risk experienced 
by women with one versus two affected grandmothers suggests that collecting family history for 
these particular second-degree relatives may be important, although collecting age at 
diagnosis in grandmothers may be unnecessary. Additionally, having two or more affected 
relatives ≥50 years was associated with a greater risk of breast cancer than having one 
affected relative <50 years, albeit with wide confidence intervals around these estimates. 
Having two or more affected aunts may also reflect having a family history on both the maternal 
and paternal side thereby leading to an increased risk. Ascertaining affected relatives by 
lineage may prove to be more meaningful for risk estimation. 
Our findings are consistent with the few studies that have reported no association 
between a first-degree family history of breast cancer and tumor subtype defined by ER/PR 
[16,33] or HER2 status [34].  In contrast, our results are discordant with the previously 
described association between a first-degree family history of breast cancer and increased 
basal-type tumor risk, possibly due to differences in the age composition of our study 
population [15].  However, our results suggest a first-degree family history may be associated 
with an increased risk of Luminal A tumors similar in magnitude to that described by Yang et al 
[15].  Since hormone negative and HER2 over-expressing tumors are more common among 
younger women [34-35], and among women with BRCA1 germline mutations [36], it is possible 
that the age composition of our study population can explain the lack of associations between 
family history and hormone negative and basal-type tumors.  Including only disease-free 
women ≥40 years may have excluded those women in the overall population who are most 
likely to be diagnosed with hormone negative and basal-type tumors, thereby attenuating our 
risk estimates. Additionally, limited statistical power due to small sample size for the tumor 
subtype analyses may have affected our risk estimates. 
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The large number of enrollees in our study allowed us to conduct an in-depth analysis 
of the relation between family history and breast cancer risk among 75,169 women with 
218,242 person-years at risk.  Additionally, we were able to examine the association between 
tumor subtype and family history. Our prospective cohort study design helped eliminate the 
potential for recall bias that may have occurred in previous retrospective cohort or case control 
studies that have examined the family history and breast cancer risk association [6].  Relative 
to other comparable prospective cohort studies, the age range and personal characteristics of 
our study subjects were also less restricted allowing our risk estimates to be generalizable to a 
larger group of women [2,30,37].  Our study was not designed to generate a risk prediction 
model to compare the risk of breast cancer across different risk factors, however, our results 
suggest that including more detailed family history in risk prediction models, such as the Gail 
model, may be important. 
There are, however, four notable limitations to our study that may have affected our 
results.  First, our risk estimates may be lower than those previously described because we 
studied only disease-free women aged ≥40 years; previous studies have suggested that the 
influence of family history on breast cancer risk may be particularly high among women <40 
years [1,7,30,38]. Secondly, the age-specific breast cancer rates observed in our cohort were 
notably higher than those estimated for the U.S. population by SEER, but were similar to 
SEER’s estimates for Washington State where the study took place [39]. This disparity may 
indicate that our results can be generalized only to regions of the U.S. that have demographic 
characteristics and screening practices similar to those in Washington State.  Thirdly, the 
proportion of women in our cohort who reported a family history of breast cancer was much 
higher than previously noted in the literature [40]. However, this may be due to our exclusion of 
women with an unknown or missing family history if they in fact had no family history of breast 
cancer, an increase in reporting of family history due to improved awareness of breast cancer 
in family members, or an increase in detection due to screening. Finally, the use of self-
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reported family history data may have resulted in misclassification and biased our risk 
estimates toward the null.  
In conclusion, our results suggest that previous estimates of the association between 
family history and breast cancer risk have been inflated, and that, in the absence of a first-
degree history, having a second-degree family history alone is not associated with an 
increased risk of breast cancer among women who have not been diagnosed with breast 
cancer before age 40.  Our study also suggests that detailed collection of family history data 
could be simplified among women ≥40 years since the age at diagnosis of family members 
does not appear to modify the risk of breast cancer.  The lineage of affected relatives may play 
a role in the determination of a woman’s risk of breast cancer and needs further exploration in 
other cohorts. 
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Table 1.  Demographic and reproductive characteristics of study subjects (N=75,169) as self-
reported on the date of study entry 
  
All Study Subjects 
Women with a 
Breast Cancer 
Diagnosis  Characteristic 
N % 
Person-
Years at 
Risk 
N % 
Breast 
Cancer 
Incidence 
Rate per 
100,0001 
Mailed Surveys2 8,793 11.7 17,324 35 3.2 202 
In Clinic Surveys3 66,376 88.3 201,100 1,052 96.8 523 
       
Age (years)       
40-44 11,887 15.8 30,064 71 6.5 236 
45-49 12,184 16.2 33,562 133 12.2 396 
50-54 15,121 20.1 43,831 158 14.5 360 
55-59 11,284 15.0 33,139 169 15.6 510 
60-64 7,302 9.7 21,763 140 12.9 643 
65-69 5,293 7.0 16,654 125 11.5 751 
70-74 4,557 6.1 14,735 108 9.9 733 
75-80 3,808 5.1 12,357 92 8.5 745 
80+ 3,733 5.0 12,318 91 8.4 739 
       
Race       
White 62,475 83.5 184,465 949 87.7 514 
Black 2,644 3.5 7,177 27 2.5 376 
American Indian 3,124 4.2 8,983 43 4.0 479 
Asian 5,857 7.8 15,514 55 5.1 355 
Other/Mixed 742 1.0 1,655 8 0.7 483 
Missing 327 -- 630 5 -- 794 
       
Body Mass Index (kg/m2)       
<25 30,911 42.9 90,324 434 41.8 480 
25-30 21,161 29.4 61,733 328 31.6 531 
30+ 19.915 27.7 56,722 277 26.7 488 
Missing 3,182 -- 9,646 48 -- 498 
       
Menopausal Status       
Pre/Peri-Menopausal 22,360 31.7 60,488 208 19.8 344 
Post-Menopausal 48,219 68.3 145,428 844 80.2 580 
Missing 4,590 -- 12,508 35 -- 280 
       
Age at Menarche (years)       
≤ 12 30,516 46.1 88,795 452 47.5 509 
13 18,950 28.6 54,740 251 26.4 459 
14 8,790 13.3 25,657 140 14.7 546 
15+ 7,987 12.1 22,620 109 11.5 482 
Missing 8,926 -- 26,612 135 -- 507 
       
Age at 1st Birth (years)       
Nulliparous 13,206 17.9 38,379 166 15.7 433 
<20 11,285 15.3 32,325 141 13.3 436 
20-24 23,337 31.6 68,376 380 35.8 556 
25-29 14,998 20.3 43,254 216 20.4 499 
30-34 7,568 10.3 22,181 115 10.8 518 
35+ 3,397 4.6 9,705 43 4.0 443 
Missing 1,378 -- 4,205 26 -- 618 
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Table 1. continued 
       
Hormone Use       
Never 35,673 48.7 97,965 429 40.5 438 
Former 17,565 23.9 48,993 248 23.4 506 
Current4 20,086 27.4 66,428 382 36.1 575 
Progestin Only 724 4.0 2,160 6 1.7 278 
Estrogen Only 8,090 43.7 26,207 118 32.9 450 
Estrogen + Progestin 9,704 52.4 33,081 235 65.4 710 
Missing 1,796 -- 5,039 28 -- 556 
       
Breast density       
Almost entirely fat 2,788 4.1 7,917 18 1.9 227 
Scattered fibroglandular tissue 20,738 30.8 62,447 203 20.8 325 
Heterogeneously dense 34,943 51.9 105,123 609 62.5 579 
Extremely dense 8,919 13.2 26,880 145 14.9 539 
Missing 7,781 -- 16,058 112 -- 697 
       
Benign Breast Biopsy History       
No 61,141 82.7 175,709 791 74.4 450 
Yes 12,831 17.3 39,218 272 25.6 694 
Missing 1,197 -- 3,497 24 -- 686 
       
Mammogram within 3 years prior  
to baseline 
    
 
No 25,658 34.1 65,237 336 30.9 515 
Yes 49,511 65.9 153,188 751 69.1 490 
1  Number of breast cancer diagnoses per 100,000 person-years 
2  Baseline questionnaire completed via mail by subject at age 40 or upon enrollment in Group Health 
3  Baseline questionnaire was filled out in clinic during a screening or diagnostic mammogram 
4  Number of specific hormone users may not add to total current hormone users due to missing data 
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Table 2.  Multivariable hazard ratios (HR) and 95% confidence intervals (CI) of breast cancer 
associated with the degree of a woman’s affected relatives1 
Relative with breast cancer Subjects Person- Years Cases 
Adjusted2 
HR (95%CI) 
     
No family history (Ref.) 44,421 127,114 558 1.0 
     
1st degree family history 14,675 44,553 314 1.54 (1.34-1.77) 
     
1st degree history only 8,355 25,329 181 1.52 (1.28-1.80) 
1st and 2nd degree history 6,320 19,224 133 1.58 (1.30-1.90) 
     
Number of affected 1st degree 
relatives     
1  12,392 37,328 252 1.51 (1.30-1.75) 
2+  1,947 6,215 56 1.76 (1.33-2.32) 
     
Age of affected 1st degree relatives     
≥50 years only 8,501 25,791 184 1.56 (1.32-1.84) 
At least one <50 years 5,177 15,723 99 1.42 (1.15-1.76) 
     
     
2nd degree family history3     
     
2nd degree history only 16,073 46,758 215 1.15 (0.98-1.35) 
     
Number of affected 2nd degree relatives    
1  10,793 31,387 158 1.25 (1.05-1.50) 
2+  5,280 15,370 57 0.94 (0.71-1.23) 
     
Age of affected 2nd degree relatives    
≥50 years only 7,283 21,262 104 1.23 (0.99-1.51) 
At least one <50 years 6,184 17,764 75 1.06 (0.84-1.36) 
     
1  Estimated using Cox Proportional Hazards Models among women in the Group Health Breast Cancer    
  Screening Program between June 1, 2001 and December 31, 2005 
2 Adjusted for age at baseline (quadratic) and stratified by source of risk factor information 
3 Among women with no affected 1st degree relatives 
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Table 3.  Multivariable hazard ratios (HR) and 95% confidence intervals (CI) of breast 
cancer associated with a woman’s specific type of affected relatives1  
Relative with breast cancer Subjects Person- Years Cases 
      Adjusted2 
     HR (95%CI) 
     
Affected Maternal History     
No Family History (Ref.) 44,421 127,114 558 1.0 
     
Affected mother 8,307 25,059 161 1.56 (1.31-1.86) 
     
Affected mother’s age at 
diagnosis (years)     
≥50 5,986 18,128 112 1.49 (1.22-1.83) 
<50 1,986 5,926 35 1.50 (1.07-2.12) 
     
     
Affected Grandmother History     
No Family History (Ref.) 44,421 127,114 558 1.0 
     
No. of affected grandmothers     
1 5,851 16,975 84 1.30 (1.03-1.64) 
2 324 930 9 2.66 (1.37-5.14) 
     
No. of affected grandmothers and 
age at diagnosis (years)     
Only affected ≥50     
1 4,211 12,240 58 1.25 (0.95-1.64) 
2 171 492 6 3.46 (1.55-7.75) 
At least one affected <50 1,733 4,989 28 1.48 (1.01-2.17) 
     
     
Affected Sister History3     
No Family History (Ref.) 32,445 92,122 390 1.0 
     
No. of affected sisters     
1 5,638 17,238 137 1.64 (1.34-2.00) 
2+ 578 1,917 20 2.03 (1.29-3.19) 
     
No. of affected sisters and age at 
diagnosis (years)     
Only affected ≥50     
1 2,753 8,504 78 1.77 (1.38-2.28) 
2+ 224 740 10 2.49 (1.32-4.70) 
At least one affected <50 2,947 8,994 59 1.50 (1.14-1.97) 
     
     
Affected Aunt History4     
No Family History (Ref.) 37,961 108,138 461 1.0 
     
No. of affected aunts     
1 11,792 34,958 188 1.30 (1.10-1.54) 
2+ 3,768 11,167 59 1.28 (0.98-1.69) 
     
No. of affected aunts and age at 
diagnosis (years)     
Only affected ≥50      
1 5,834 17,376 100 1.38 (1.11-1.72) 
2+ 1,251 3,740 27 1.68 (1.14-2.48) 
At least one affected <50 5,042 14,668 65 1.10 (0.85-1.43) 
1  Estimated using Cox Proportional Hazards Models among women in the Group Health Breast 
  Cancer  Screening Program between June 1, 2001 and December 31, 2005 
2 Adjusted for age at baseline (quadratic) and stratified by source of risk factor information 
3 Among women with ≥1 sister who had complete sister history data 
4 Among women with ≥1 aunt who had complete aunt history data 
  
Table 4.  Age-adjusted hazard ratios (HR) and 95% confidence intervals (CI) of breast cancer tumor subtype associated 
with the degree of affected relatives1  
 ER+/PR+ ER+/PR- ER-/PR- 
Relative with breast cancer N         HR
1  
        (95%CI) N 
        HR1  
        (95%CI) N 
        HR2  
       (95%CI) 
       
No family history (Ref.) 336 1.0 33 1.0 75 1.0 
2nd degree history only 124 1.11 (0.91-1.37) 17 1.60 (0.89-2.87) 27 1.02 (0.66-1.59) 
Any 1st degree history 181 1.49 (1.24-1.78) 29 2.43 (1.47-4.01) 36 1.36 (0.91-2.03) 
1  Estimated using Cox Proportional Hazards models among women in the Group Health Breast Cancer Screening Program between  
   June 1, 2001 and December 31, 2005 
2 Adjusted for age at baseline (quadratic) 
 
 
 
 
Table 5.  Age adjusted hazard ratios (HR) and 95% confidence intervals (CI) of breast cancer tumor subtype associated with the degree of affected 
relatives1  
 Luminal A2 Luminal B3 HER2-neu Over-expressing4 Basal
5 
Relative with breast cancer N         HR
6  
        (95%CI) N 
        HR6  
        (95%CI) N 
        HR6  
        (95%CI) N 
        HR6  
        (95%CI) 
         
No family history (Ref.) 191 1.0 11 1.0 5 1.0 36 1.0 
2nd degree history only 75 1.23 (0.94-1.61) 8 1.98 (0.79-4.94) 9 4.87 (1.62-14.6) 4 0.33 (0.12-0.93) 
Any 1st degree history 125 1.78 (1.42-2.23) 8 2.10 (0.84-5.22) 5 2.91 (0.84-10.1) 13 1.01 (0.53-1.90) 
1  Estimated using Cox Proportional Hazards models among women in the Group Health Breast Cancer Screening Program between June 1, 2001 and  
   December 31, 2005 
2 ER+ and/or PR+, HER2- 
3 ER+ and/or PR+, HER2+ 
4 ER-, PR-, HER2+ 
5 ER-, PR-, HER2- 
6 Adjusted for age at baseline (quadratic) 
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APPENDICES 
 
Appendix A. Description of family history classification for study subjects  
 
Family History Exposure 
 
Family History of Women Included1 
  
No family history No relatives with a positive history of breast cancer (Referent group for all 
analyses) 
  
1st degree family history  
  
1st degree history only ≥ 1 affected first-degree relatives, no affected second- degree relatives 
1st and 2nd degree history ≥ 1 affected first AND second-degree relatives 
  
Number of affected 1st degree relatives 
1 1 affected first-degree relative, regardless of second-degree history 
≥ 2 ≥ 2 affected first-degree relatives, regardless of second-degree history 
  
Age of affected 1st degree relatives  
≥ 50 years only 
≥ 1 affected first-degree relative diagnosed ≥ 50 years, none diagnosed < 50 
years, regardless of second-degree history 
At least one <50 years  
≥ 1 affected first-degree relative diagnosed < 50 years, regardless of  second-
degree history 
  
2nd degree family history  
  
2nd degree history only ≥ 1 affected second-degree relative, no affected first-degree relatives 
  
Number of affected 2nd degree relatives 
1 1 affected second-degree relative, no affected first-degree relatives 
≥ 2 ≥ 2 affected second-degree relatives, no affected first-degree relatives 
  
Age of affected 2nd degree relatives  
≥ 50 years only 
≥ 1 affected second-degree relative diagnosed ≥ 50 years, none diagnosed < 
50 years, and no first-degree history 
At least one <50 years 
≥ 1 affected second-degree relative diagnosed < 50 years and no first-degree 
history 
  
Specific Relative History2  
  
Number of affected relatives  
1 1 affected specific relative 
≥ 2 ≥ 2 affected specific relatives 
  
Number of affected relatives and age 
at diagnosis  
Only affected ≥ 50 years  
1 1 relative diagnosed ≥ 50 years, none diagnosed < 50 years 
≥ 2  ≥ 2 relatives diagnosed ≥ 50 years, none diagnosed < 50 years 
≥ 1 relative < 50 years At least 1 relative diagnosed < 50 years 
1 In only female relatives: mother, sister(s), aunt(s), daughter(s) 
2  For grandmother, sister, and aunt history 
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